Browse Gene Sets

Gene set name:

 
  (Enter full or partial name)

By first letter:

 

1 2 3 4 5 6 7 8 9 0 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

By collection:

[about the MSigDB collections]

  • H (hallmark gene sets, 50 gene sets)
  • C1 (positional gene sets, 278 gene sets)
  • C2 (curated gene sets, 6290 gene sets)
    • CGP (chemical and genetic perturbations, 3368 gene sets)
    • CP (canonical pathways, 2922 gene sets)
  • C3 (regulatory target gene sets, 3731 gene sets)
    • MIR (microRNA targets, 2598 gene sets)
    • TFT (all transcription factor targets, 1133 gene sets)
      • TFT:GTRD (GTRD transcription factor targets, 523 gene sets)
      • TFT:TFT_Legacy (legacy transcription factor targets, 610 gene sets)
  • C4 (computational gene sets, 858 gene sets)
    • CGN (cancer gene neighborhoods, 427 gene sets)
    • CM (cancer modules, 431 gene sets)
  • C5 (ontology gene sets, 14998 gene sets)
    • GO (Gene Ontology, 10185 gene sets)
      • GO:BP (GO biological process, 7481 gene sets)
      • GO:CC (GO cellular component, 996 gene sets)
      • GO:MF (GO molecular function, 1708 gene sets)
    • HPO (Human Phenotye Ontology, 4813 gene sets)
  • C6 (oncogenic signature gene sets, 189 gene sets)
  • C7 (immunologic signature gene sets, 5219 gene sets)
    • IMMUNESIGDB (ImmuneSigDB gene sets, 4872 gene sets)
    • VAX (vaccine response gene sets, 347 gene sets)
  • C8 (cell type signature gene sets, 671 gene sets)

Gene sets starting with V

Click on a gene set name to view its gene set page.

VACUOLAR_PART
VALK_AML_CLUSTER_1
VALK_AML_CLUSTER_10
VALK_AML_CLUSTER_11
VALK_AML_CLUSTER_12
VALK_AML_CLUSTER_13
VALK_AML_CLUSTER_15
VALK_AML_CLUSTER_16
VALK_AML_CLUSTER_2
VALK_AML_CLUSTER_3
VALK_AML_CLUSTER_4
VALK_AML_CLUSTER_5
VALK_AML_CLUSTER_6
VALK_AML_CLUSTER_7
VALK_AML_CLUSTER_8
VALK_AML_CLUSTER_9
VALK_AML_WITH_11Q23_REARRANGED
VALK_AML_WITH_CEBPA
VALK_AML_WITH_EVI1
VALK_AML_WITH_FLT3_ITD
VALK_AML_WITH_T_8_21_TRANSLOCATION
VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_
INFANT_STIMULATED_VS_UNSTIMULATED_8
MO_UP

VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_
INFANT_STIMULATED_VS_UNSTIMULATED_9
MO_DN

VAN_DEN_BIGGELAAR_PBMC_PREVNAR_9MO_
INFANT_STIMULATED_VS_UNSTIMULATED_9
MO_UP

VANASSE_BCL2_TARGETS_DN
VANASSE_BCL2_TARGETS_UP
VANDESLUIS_COMMD1_TARGETS_GROUP_2_U
P

VANDESLUIS_COMMD1_TARGETS_GROUP_3_D
N

VANDESLUIS_COMMD1_TARGETS_GROUP_3_U
P

VANDESLUIS_COMMD1_TARGETS_GROUP_4_D
N

VANDESLUIS_COMMD1_TARGETS_GROUP_4_U
P

VANDESLUIS_NORMAL_EMBRYOS_DN
VANDESLUIS_NORMAL_EMBRYOS_UP
VANHARANTA_UTERINE_FIBROID_DN
VANHARANTA_UTERINE_FIBROID_UP
VANHARANTA_UTERINE_FIBROID_WITH_7Q_
DELETION_DN

VANHARANTA_UTERINE_FIBROID_WITH_7Q_
DELETION_UP

VANLOO_SP3_TARGETS_DN
VANLOO_SP3_TARGETS_UP
VANOEVELEN_MYOGENESIS_SIN3A_TARGETS
VANTVEER_BREAST_CANCER_BRCA1_DN
VANTVEER_BREAST_CANCER_BRCA1_UP
VANTVEER_BREAST_CANCER_ESR1_DN
VANTVEER_BREAST_CANCER_ESR1_UP
VANTVEER_BREAST_CANCER_METASTASIS_D
N

VANTVEER_BREAST_CANCER_METASTASIS_U
P

VANTVEER_BREAST_CANCER_POOR_PROGNOS
IS

VARELA_ZMPSTE24_TARGETS_DN
VARELA_ZMPSTE24_TARGETS_UP
VART_KSHV_INFECTION_ANGIOGENIC_MARK
ERS_DN

VART_KSHV_INFECTION_ANGIOGENIC_MARK
ERS_UP

VDR_Q3
VDR_Q6
VECCHI_GASTRIC_CANCER_ADVANCED_VS_E
ARLY_DN

VECCHI_GASTRIC_CANCER_ADVANCED_VS_E
ARLY_UP

VECCHI_GASTRIC_CANCER_EARLY_DN
VECCHI_GASTRIC_CANCER_EARLY_UP
VEGF_A_UP.V1_DN
VEGF_A_UP.V1_UP
VERHAAK_AML_WITH_NPM1_MUTATED_DN
VERHAAK_AML_WITH_NPM1_MUTATED_UP
VERHAAK_GLIOBLASTOMA_CLASSICAL
VERHAAK_GLIOBLASTOMA_MESENCHYMAL
VERHAAK_GLIOBLASTOMA_NEURAL
VERHAAK_GLIOBLASTOMA_PRONEURAL
VERNELL_RETINOBLASTOMA_PATHWAY_DN
VERNELL_RETINOBLASTOMA_PATHWAY_UP
VERNOCHET_ADIPOGENESIS
VERRECCHIA_DELAYED_RESPONSE_TO_TGFB
1

VERRECCHIA_EARLY_RESPONSE_TO_TGFB1
VERRECCHIA_RESPONSE_TO_TGFB1_C1
VERRECCHIA_RESPONSE_TO_TGFB1_C2
VERRECCHIA_RESPONSE_TO_TGFB1_C3
VERRECCHIA_RESPONSE_TO_TGFB1_C4
VERRECCHIA_RESPONSE_TO_TGFB1_C5
VERRECCHIA_RESPONSE_TO_TGFB1_C6
VESICLE
VESICLE_MEDIATED_TRANSPORT
VESICULAR_FRACTION
VETTER_TARGETS_OF_PRKCA_AND_ETS1_DN
VETTER_TARGETS_OF_PRKCA_AND_ETS1_UP
VICENT_METASTASIS_UP
VIETOR_IFRD1_TARGETS
VILIMAS_NOTCH1_TARGETS_DN
VILIMAS_NOTCH1_TARGETS_UP
VILLANUEVA_LIVER_CANCER_KRT19_DN
VILLANUEVA_LIVER_CANCER_KRT19_UP
VISALA_AGING_LYMPHOCYTE_DN
VISALA_AGING_LYMPHOCYTE_UP
VISALA_RESPONSE_TO_HEAT_SHOCK_AND_A
GING_DN

VISALA_RESPONSE_TO_HEAT_SHOCK_AND_A
GING_UP

VOIGT_PBMC_FLUARIX_AGE_50_74YO_FEMA
LES_VS_MALES_0DY_TO_28D_UP

VRTN_TARGET_GENES